Drug Profile

DSP 1181

Alternative Names: DSP-1181

Latest Information Update: 29 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sumitomo Dainippon Pharma
Developer Sumitomo Pharma
Class Behavioural disorder therapies; Small molecules
Mechanism of Action 5-HT1A serotonin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Obsessive-compulsive disorders

Most Recent Events

20 Nov 2024 Exscientia has been acquired and merged into Recursion Pharmaceuticals
01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
03 Feb 2022 Discontinued - Phase-I for Obsessive-compulsive disorders in Japan (PO) (Sumitomo Dainippon Pharma pipeline, February 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com